Download PDF
CC BY-NC-ND 4.0 · Endosc Int Open 2021; 09(09): E1435-E1444
DOI: 10.1055/a-1497-1801
Original article

Observed risk of recurrent bleeding and thromboembolic disease in COVID-19 patients with gastrointestinal bleeding

Emmanuel Attah
1   Medicine, Weill Cornell Internal Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Tracey A. Martin
2   Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Emily S. Smith
1   Medicine, Weill Cornell Internal Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Sunena Tewani
3   Division of Hospital Medicine, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Kaveh Hajifathalian
2   Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Reem Z. Sharaiha
2   Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
,
Carl V. Crawford
2   Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
,
David Wan
2   Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York Presbyterian Hospital, New York, New York, United States
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Background and study aim COVID-19 patients are at increased risk for venous thromboembolism (VTE) requiring the use of anticoagulation. Gastrointestinal bleeding (GIB) is increasingly being reported, complicating the decision to initiate or resume anticoagulation as providers balance the risk of thrombotic disease with the risk of bleeding. Our study aimed to assess rebleeding rates in COVID-19 patients with GIB and determine whether endoscopy reduces these rebleeding events. We also report 30-day VTE and mortality rates.

Methods This was a retrospective study evaluating 56 COVID-19 patients with GIB for the following outcomes: 30-day rebleeding rate, 30-day VTE rate, effects of endoscopic intervention on the rate of rebleeding, and 30-day mortality.

Results The overall rates of VTE and rebleeding events were 27 % and 41 %, respectively. Rebleeding rates in patients managed conservatively was 42 % compared with 40 % in the endoscopy group. Overall, 87 % of those who underwent invasive intervention resumed anticoagulation vs. 55 % of those managed medically (P = 0.02). The all-cause 30-day mortality and GIB-related deaths were 32 % and 9 %, respectively. Mortality rates between the endoscopic and conservative management groups were not statistically different (25 % vs. 39 %; P = 0.30).

Conclusions Although rebleeding rates were similar between the endoscopic and conservative management groups, patients who underwent intervention were more likely to restart anticoagulation. While endoscopy appeared to limit the duration that anticoagulation was withheld, larger studies are needed to further characterize its direct effect on mortality outcomes in these complex patients.



Publication History

Received: 18 December 2020

Accepted: 14 April 2021

Article published online:
23 August 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Lin L, Jiang X, Zhang Z. et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut 2020; 69: 997-1001
    CrossrefPubMedGoogle Scholar
  • 2 Cheung KS, Hung IFN, Chan PPY. et al. Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis. Gastroenterology 2020; 159: 81-95
    CrossrefPubMedGoogle Scholar
  • 3 Mao R, Qiu Y, He JS. et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 667-678 erratum in Lancet Gastroenterol Hepatol 2020; 5: e6
    CrossrefPubMedGoogle Scholar
  • 4 Martin TA, Wan DW, Hajifathalian K. et al. Gastrointestinal bleeding in patients with coronavirus disease 2019: a matched case–control study. Am J Gastroenterol 2020; 115: 1609-1616
    CrossrefPubMedGoogle Scholar
  • 5 Hippisley-Cox J, Coupland C. Predicting risk of upper gastrointestinal bleed and intracranial bleed with anticoagulants: cohort study to derive and validate the QBleed scores. BMJ 2014; 349: g4606
    CrossrefPubMedGoogle Scholar
  • 6 Ray WA, Chung CP, Murray KT. et al. Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding. JAMA 2018; 320: 2221-2230
    CrossrefPubMedGoogle Scholar
  • 7 Chen WC, Chen YH, Hsu PI. et al. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed Res Int 2014; 2014: 463767
    PubMedGoogle Scholar
  • 8 Landefeld CS, Beyth RJ. Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 1993; 95: 315-328
    CrossrefPubMedGoogle Scholar
  • 9 Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood 2020; 135: 2033-2040
    CrossrefPubMedGoogle Scholar
  • 10 Bilaloglu S, Aphinyanaphongs Y, Jones S. et al. Thrombosis in hospitalized patients with COVID-19 in a New York City health system. JAMA 2020; 324: 799-801
    CrossrefPubMedGoogle Scholar
  • 11 Trigonis RA, Holt DB, Yuan R. et al. Incidence of venous thromboembolism in critically ill coronavirus disease 2019 patients receiving prophylactic anticoagulation. Crit Care Med 2020; 48: e805-e808
    CrossrefPubMedGoogle Scholar
  • 12 Middeldorp S, Coppens M, van Haaps TF. et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost 2020; 18: 1995-2002
    CrossrefPubMedGoogle Scholar
  • 13 Billett HH, Reyes-Gil M, Szymanski J. et al. Anticoagulation in COVID-19: effect of enoxaparin, heparin, and apixaban on mortality. Thromb Haemost 2020; 120: 1691-1699
    Article in Thieme ConnectPubMedGoogle Scholar
  • 14 Rico-Mesa JS, Rosas D, Ahmadian-Tehrani A. et al. The role of anticoagulation in COVID-19-induced hypercoagulability. Curr Cardiol Rep 2020; 22: 53
    CrossrefPubMedGoogle Scholar
  • 15 Lau JYW, Yu Y, Tang RSY. et al. Timing of endoscopy for acute upper gastrointestinal bleeding. N Engl J Med 2020; 382: 1299-1308
    CrossrefPubMedGoogle Scholar
  • 16 Strate LL, Gralnek IM. ACG clinical guideline: management of patients with acute lower gastrointestinal bleeding. Am J Gastroenterol 2016; 111: 459-474
    CrossrefPubMedGoogle Scholar
  • 17 Shalimar D, Vaishnav M, Elhence A. et al. Outcome of conservative therapy in COVID-19 patients presenting with gastrointestinal bleeding. J Clin Exp Hepatol 2020; 11: 327-333
    PubMedGoogle Scholar
  • 18 Richardson S, Hirsch JS, Narasimhan M. et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020; 323: 2052
    CrossrefPubMedGoogle Scholar
  • 19 Horby P, Lim WS. RECOVERY Collaborative Group. et al. Dexamethasone in hospitalized patients with Covid-19 – preliminary report. N Engl J Med 2021; 384: 693-704
    CrossrefPubMedGoogle Scholar
  • 20 Maggio D, Barkun AN, Martel M. et al. Predictors of early rebleeding after endoscopic therapy in patients with nonvariceal upper gastrointestinal bleeding secondary to high-risk lesions. Can J Gastroenterol 2013; 27: 454-458
    CrossrefPubMedGoogle Scholar
  • 21 Barkun A, Sabbah S, Enns R. et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. Am J Gastroenterol 2004; 99: 1238-1246
    CrossrefPubMedGoogle Scholar
  • 22 Kahi CJ, Jensen DM, Sung JJY. et al. Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology 2005; 129: 855-862
    CrossrefPubMedGoogle Scholar
  • 23 Witt DM. What to do after the bleed: resuming anticoagulation after major bleeding. Hematology 2016; 2016: 620-624
    CrossrefPubMedGoogle Scholar
  • 24 Goldstein JN, Greenberg SM. Should anticoagulation be resumed after intracerebral hemorrhage?. Cleve Clin J Med 2010; 77: 791-799
    CrossrefPubMedGoogle Scholar
  • 25 Qureshi W, Mittal C, Patsias I. et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014; 113: 662-668
    CrossrefPubMedGoogle Scholar